Pharmaceutical Industry in China
Favorable economic conditions are expected to continue to boost the growth of the pharmaceutical industry in China. The health of the pharmaceutical industry has been improving continuously since 2000 and is expected to get even better.
The Chinese pharmaceuticals market is forecast to become the world's firth largest by 2010 - and the largest by 2050. There are still greater market access following China's entry into the World Trade Organization (WTO), multinational investors continue to face a range of obstacles, many of which stem from the legacy of central planning of the industry. These include complex distribution, under-developed retail options, intellectual property infringements and pricing controls and pressures. At the same time, the continuing reliance of leading domestic companies on generic drugs has prevented the emergence of Chinese brands.
However, the industry is still small-scale, with a scattered geographical layout, duplicated production processes, and outdated manufacturing technology and management structure. The Chinese pharmaceutical industry also has a lower market concentration and weak international trading competitiveness, coupled with a lack of patented pharmaceuticals developed in-house.
Aruvian's R'search’s report Pharmaceutical Industry in China explores the Chinese Pharmaceutical Industry landscape from the basics to the issues facing the industry today. The report delves in to the WTO accession of China and the impact it has had on the Chinese Pharmaceutical Industry, growth trends in the industry, competition in the industry, etc.
The report also analyzes the Chinese pharmaceutical industry through three frameworks – a SWOT analysis, a PEST analysis, and a Porter’s Five Forces Business Strategy analysis. The report also looks at strategies for market entry, the role of R&D in the Chinese Pharmaceutical Industry, the role of the government in the industry, and investment opportunities in China’s Pharmaceutical Industry.
Complete with a comprehensive section on the clinical trials, market investment opportunities, an analysis of the fifteen leading players in the Chinese Pharmaceutical Industry, Aruvian’s latest research is a collection of all you need to know about China’s Pharmaceutical Industry.
The Chinese pharmaceuticals market is forecast to become the world's firth largest by 2010 - and the largest by 2050. There are still greater market access following China's entry into the World Trade Organization (WTO), multinational investors continue to face a range of obstacles, many of which stem from the legacy of central planning of the industry. These include complex distribution, under-developed retail options, intellectual property infringements and pricing controls and pressures. At the same time, the continuing reliance of leading domestic companies on generic drugs has prevented the emergence of Chinese brands.
However, the industry is still small-scale, with a scattered geographical layout, duplicated production processes, and outdated manufacturing technology and management structure. The Chinese pharmaceutical industry also has a lower market concentration and weak international trading competitiveness, coupled with a lack of patented pharmaceuticals developed in-house.
Aruvian's R'search’s report Pharmaceutical Industry in China explores the Chinese Pharmaceutical Industry landscape from the basics to the issues facing the industry today. The report delves in to the WTO accession of China and the impact it has had on the Chinese Pharmaceutical Industry, growth trends in the industry, competition in the industry, etc.
The report also analyzes the Chinese pharmaceutical industry through three frameworks – a SWOT analysis, a PEST analysis, and a Porter’s Five Forces Business Strategy analysis. The report also looks at strategies for market entry, the role of R&D in the Chinese Pharmaceutical Industry, the role of the government in the industry, and investment opportunities in China’s Pharmaceutical Industry.
Complete with a comprehensive section on the clinical trials, market investment opportunities, an analysis of the fifteen leading players in the Chinese Pharmaceutical Industry, Aruvian’s latest research is a collection of all you need to know about China’s Pharmaceutical Industry.
A. EXECUTIVE SUMMARY
B. THE GLOBAL PHARMACEUTICAL INDUSTRY – A BRIEF PROFILE
B.1 Industry Definition
B.2 Product Characterization
B.2 Industry Overview
B.3 Industry Forecast
C. CHINA PHARMACEUTICAL INDUSTRY
C.1 Industry Definition
C.2 Industry Overview
C.3 Market Segments
C.4 Competition in the Industry
C.5 Growth Factors
C.6 Challenges & Barriers in the Industry
D. OTC PHARMACEUTICALS IN CHINA
D.1 Sector Definition
D.2 Sector Overview
D.3 Market Segments
D.4 Market Share
D.5 Competition in the Sector
D.6 Distribution Channels
D.7 Sector Forecast
E. GENERICS SECTOR IN CHINA
E.1 Sector Definition
E.2 Sector Overview
E.3 Market Segments
E.4 Competition in the Sector
E.5 Sector Forecast
F. MARKET TRENDS & GROWTH OPPORTUNITIES
G. REGULATORY DEVELOPMENTS & FRAMEWORK
H. CHINA PHARMACEUTICAL INDUSTRY – SWOT FRAMEWORK ANALYSIS
H.1 Strength Factors
H.2 Weakness Factors
H.3 Opportunity Factors
H.4 Threat Factors
I. CHINA PHARMACEUTICAL INDUSTRY – PEST FRAMEWORK ANALYSIS
I.1 Political Features
I.2 Economic Features
I.3 Social Features
I.4 Technological Features
J. CHINA PHARMACEUTICAL INDUSTRY – PORTER’S FIVE FORCES BUSINESS STRATEGY ANALYSIS
J.1 Bargaining Power of Buyers
J.2 Bargaining Power of Suppliers
J.3 Competitive Rivalry in the Industry
J.4 Threat of New Entrants
J.5 Threat of Substitutes
J.6 Conclusion
K. EVOLVING STRATEGIC OPTIONS FOR CHINESE COMPANIES
K.1 Competitive Business Models
K.2 Cooperative Strategies
L. IMPACT OF CHANGING IP LAWS ON PRODUCT LEVEL ACCESS TO MEDICINES IN CHINA
L.1 Generic ARVs
L.2 Patented ARVs
M. INVESTMENT OPTIONS IN CHINA’S PHARMACEUTICAL INDUSTRY
M.1 Distribution System
M.2 Hospitals vs. Pharmacies
M.3 Growth of OTC
M.4 IP Protection
M.5 China’s Drug Pricing Policy
M.6 Role of Market Consolidation
M.7 China – An Attractive Destination for Pharma R&D
M.8 Outlook for Investment in the Sector
N. CHINA’S WTO ACCESSION – CHALLENGES & OPPORTUNITIES
O. CONTRACT RESEARCH SERVICES IN CHINA’S PHARMA SECTOR
P. CHINA’S PHARMACEUTICAL INDUSTRY – FUTURE PERSPECTIVE
Q. MAJOR INDUSTRY PLAYERS
Q.1 AstraZeneca PLC
Q.2 Bayer AG
Q.3 Beijing Double-Crane Pharmaceutical (DCPC)
Q.4 Beijing TongRenTang Co., Ltd.
Q.5 GlaxoSmithKline Plc
Q.6 Guilin Sanjin Pharmaceutical Co., Ltd.
Q.7 Northeast Pharmaceutical Group (NEPG)
Q.8 Novartis AG
Q.9 Pfizer Inc
Q.10 Roche Holding AG
Q.11 Sanjiu Medical and Pharmaceutical Co. Ltd. (SMPCL)
Q.12 Shanghai Pharmaceutical (Group) Co. Ltd (SPCL)
Q.13 STADA Arzneimittel
Q.14 Wuhan Grand Pharmaceutical
Q.15 Yunnan Baiyao Group Co., Ltd.
R. APPENDIX
S. GLOSSARY OF TERMS
B. THE GLOBAL PHARMACEUTICAL INDUSTRY – A BRIEF PROFILE
B.1 Industry Definition
B.2 Product Characterization
B.2 Industry Overview
B.3 Industry Forecast
C. CHINA PHARMACEUTICAL INDUSTRY
C.1 Industry Definition
C.2 Industry Overview
C.3 Market Segments
C.4 Competition in the Industry
C.5 Growth Factors
C.6 Challenges & Barriers in the Industry
D. OTC PHARMACEUTICALS IN CHINA
D.1 Sector Definition
D.2 Sector Overview
D.3 Market Segments
D.4 Market Share
D.5 Competition in the Sector
D.6 Distribution Channels
D.7 Sector Forecast
E. GENERICS SECTOR IN CHINA
E.1 Sector Definition
E.2 Sector Overview
E.3 Market Segments
E.4 Competition in the Sector
E.5 Sector Forecast
F. MARKET TRENDS & GROWTH OPPORTUNITIES
G. REGULATORY DEVELOPMENTS & FRAMEWORK
H. CHINA PHARMACEUTICAL INDUSTRY – SWOT FRAMEWORK ANALYSIS
H.1 Strength Factors
H.2 Weakness Factors
H.3 Opportunity Factors
H.4 Threat Factors
I. CHINA PHARMACEUTICAL INDUSTRY – PEST FRAMEWORK ANALYSIS
I.1 Political Features
I.2 Economic Features
I.3 Social Features
I.4 Technological Features
J. CHINA PHARMACEUTICAL INDUSTRY – PORTER’S FIVE FORCES BUSINESS STRATEGY ANALYSIS
J.1 Bargaining Power of Buyers
J.2 Bargaining Power of Suppliers
J.3 Competitive Rivalry in the Industry
J.4 Threat of New Entrants
J.5 Threat of Substitutes
J.6 Conclusion
K. EVOLVING STRATEGIC OPTIONS FOR CHINESE COMPANIES
K.1 Competitive Business Models
K.2 Cooperative Strategies
L. IMPACT OF CHANGING IP LAWS ON PRODUCT LEVEL ACCESS TO MEDICINES IN CHINA
L.1 Generic ARVs
L.2 Patented ARVs
M. INVESTMENT OPTIONS IN CHINA’S PHARMACEUTICAL INDUSTRY
M.1 Distribution System
M.2 Hospitals vs. Pharmacies
M.3 Growth of OTC
M.4 IP Protection
M.5 China’s Drug Pricing Policy
M.6 Role of Market Consolidation
M.7 China – An Attractive Destination for Pharma R&D
M.8 Outlook for Investment in the Sector
N. CHINA’S WTO ACCESSION – CHALLENGES & OPPORTUNITIES
O. CONTRACT RESEARCH SERVICES IN CHINA’S PHARMA SECTOR
P. CHINA’S PHARMACEUTICAL INDUSTRY – FUTURE PERSPECTIVE
Q. MAJOR INDUSTRY PLAYERS
Q.1 AstraZeneca PLC
Q.2 Bayer AG
Q.3 Beijing Double-Crane Pharmaceutical (DCPC)
Q.4 Beijing TongRenTang Co., Ltd.
Q.5 GlaxoSmithKline Plc
Q.6 Guilin Sanjin Pharmaceutical Co., Ltd.
Q.7 Northeast Pharmaceutical Group (NEPG)
Q.8 Novartis AG
Q.9 Pfizer Inc
Q.10 Roche Holding AG
Q.11 Sanjiu Medical and Pharmaceutical Co. Ltd. (SMPCL)
Q.12 Shanghai Pharmaceutical (Group) Co. Ltd (SPCL)
Q.13 STADA Arzneimittel
Q.14 Wuhan Grand Pharmaceutical
Q.15 Yunnan Baiyao Group Co., Ltd.
R. APPENDIX
S. GLOSSARY OF TERMS
